News Releases
View printer-friendly version < < backNet earnings and diluted earnings per share for the second quarter of 2012 were
"Our talented associates around the world are building a strong foundation for sustainable growth through meaningful innovations and an expanding global footprint. Our pharmaceutical pipeline continued its strong momentum this quarter with the submission of several new drug applications, as well as strong growth from several recently launched products that meet critical patient needs," said
The Company adjusted its earnings guidance for full-year 2012 to
Worldwide Consumer sales of
Positive contributors to operational results were international sales of oral care products; NEUTROGENA® skin care products; and international baby care products.
Worldwide Pharmaceutical sales of
Positive contributors to international sales were strong results for REMICADE® (infliximab), a biologic approved for the treatment of a number of immune-mediated, inflammatory diseases, primarily related to incremental sales from international territories included in the amended distribution agreement with Merck; PREZISTA® (darunavir), a treatment for HIV; and sales of recently launched products.
The strong sales results of recently launched products include ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone, for the treatment of metastatic, castration-resistant prostate cancer; INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the acute and maintenance treatment of schizophrenia in adults; international sales of INCIVO® (telaprevir), a direct acting antiviral protease inhibitor, for the treatment of genotype-1 chronic hepatitis C virus, in combination with peginterferon alfa and ribavirin, in adults; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; and XARELTO® (rivaroxaban), an oral anticoagulant.
Sales results in the U.S. were negatively impacted by generic competition for LEVAQUIN® (levofloxacin), a treatment for bacterial infections, and the manufacturing suspension at a third party supplier for DOXIL® (doxorubicin HCl liposome injection)/CAELYX® (pegylated liposomal doxorubicin hydrochloride), a medication to treat ovarian and other cancers.
During the quarter, several drug marketing applications were submitted in the
Also during the quarter,
Worldwide Medical Devices and Diagnostics sales of
Primary contributors to operational growth were orthopaedic sales from the recently completed acquisition of Synthes;
During the quarter, the Company announced the completion of the acquisition of Synthes for
In addition,
About
Caring for the world, one person at a time...inspires and unites the people of
* Net earnings and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company's website at www.investor.jnj.com.
NOTE TO INVESTORS
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, condensed consolidated statements of earnings, and sales of key products/franchises. Additional information on
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation; impact of business
combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of
|
|||||||||||||||||||
Supplementary Sales Data |
|||||||||||||||||||
(Unaudited; Dollars in Millions) |
SECOND QUARTER |
SIX MONTHS | |||||||||||||||||
Percent Change |
Percent Change |
||||||||||||||||||
2012 |
2011 |
Total |
Operations |
Currency |
2012 |
2011 |
Total |
Operations |
Currency | ||||||||||
Sales to customers by |
|||||||||||||||||||
segment of business |
|||||||||||||||||||
Consumer |
|||||||||||||||||||
U.S. |
$ 1,313 |
1,339 |
(1.9) |
% |
(1.9) |
- |
$ 2,629 |
2,684 |
(2.0) |
% |
(2.0) |
- | |||||||
International |
2,306 |
2,454 |
(6.0) |
2.0 |
(8.0) |
4,585 |
4,791 |
(4.3) |
1.2 |
(5.5) | |||||||||
3,619 |
3,793 |
(4.6) |
0.6 |
(5.2) |
7,214 |
7,475 |
(3.5) |
- |
(3.5) | ||||||||||
Pharmaceutical |
|||||||||||||||||||
U.S. |
3,094 |
3,239 |
(4.5) |
(4.5) |
- |
6,120 |
6,630 |
(7.7) |
(7.7) |
- | |||||||||
International |
3,197 |
2,994 |
6.8 |
15.5 |
(8.7) |
6,304 |
5,662 |
11.3 |
17.3 |
(6.0) | |||||||||
6,291 |
6,233 |
0.9 |
5.1 |
(4.2) |
12,424 |
12,292 |
1.1 |
3.9 |
(2.8) | ||||||||||
Med Devices & Diagnostics |
|||||||||||||||||||
U.S. |
2,953 |
2,869 |
2.9 |
2.9 |
- |
5,830 |
5,741 |
1.6 |
1.6 |
- | |||||||||
International |
3,612 |
3,702 |
(2.4) |
3.8 |
(6.2) |
7,146 |
7,262 |
(1.6) |
2.2 |
(3.8) | |||||||||
6,565 |
6,571 |
(0.1) |
3.4 |
(3.5) |
12,976 |
13,003 |
(0.2) |
1.9 |
(2.1) | ||||||||||
U.S. |
7,360 |
7,447 |
(1.2) |
(1.2) |
- |
14,579 |
15,055 |
(3.2) |
(3.2) |
- | |||||||||
International |
9,115 |
9,150 |
(0.4) |
7.1 |
(7.5) |
18,035 |
17,715 |
1.8 |
6.8 |
(5.0) | |||||||||
Worldwide |
|
16,597 |
(0.7) |
% |
3.5 |
(4.2) |
|
32,770 |
(0.5) |
% |
2.2 |
(2.7) |
|
|||||||||||||||||||
Supplementary Sales Data | |||||||||||||||||||
(Unaudited; Dollars in Millions) |
SECOND QUARTER |
SIX MONTHS | |||||||||||||||||
Percent Change |
Percent Change |
||||||||||||||||||
2012 |
2011 |
Total |
Operations |
Currency |
2012 |
2011 |
Total |
Operations |
Currency | ||||||||||
Sales to customers by |
|||||||||||||||||||
geographic area |
|||||||||||||||||||
U.S. |
$ 7,360 |
7,447 |
(1.2) |
% |
(1.2) |
- |
|
15,055 |
(3.2) |
% |
(3.2) |
- | |||||||
|
4,165 |
4,543 |
(8.3) |
1.6 |
(9.9) |
8,359 |
8,726 |
(4.2) |
2.9 |
(7.1) | |||||||||
Western Hemisphere excluding U.S. |
1,728 |
1,543 |
12.0 |
22.4 |
(10.4) |
3,442 |
2,979 |
15.5 |
22.7 |
(7.2) | |||||||||
|
3,222 |
3,064 |
5.2 |
7.7 |
(2.5) |
6,234 |
6,010 |
3.7 |
4.5 |
(0.8) | |||||||||
International |
9,115 |
9,150 |
(0.4) |
7.1 |
(7.5) |
18,035 |
17,715 |
1.8 |
6.8 |
(5.0) | |||||||||
Worldwide |
|
16,597 |
(0.7) |
% |
3.5 |
(4.2) |
|
32,770 |
(0.5) |
% |
2.2 |
(2.7) |
|
|||||||||
Condensed Consolidated Statement of Earnings |
|||||||||
(Unaudited; in Millions Except Per Share Figures) |
SECOND QUARTER | ||||||||
2012 |
2011 |
Percent | |||||||
Percent |
Percent |
Increase | |||||||
Amount |
to Sales |
Amount |
to Sales |
(Decrease) | |||||
Sales to customers |
|
100.0 |
|
100.0 |
(0.7) | ||||
Cost of products sold |
5,143 |
31.2 |
5,172 |
31.2 |
(0.6) | ||||
Selling, marketing and administrative expenses |
4,965 |
30.1 |
5,215 |
31.4 |
(4.8) | ||||
Research and development expense |
1,766 |
10.7 |
1,882 |
11.3 |
(6.2) | ||||
In-process research and development |
429 |
2.6 |
- |
- |
|||||
Interest (income) expense, net |
129 |
0.8 |
111 |
0.7 |
|||||
Other (income) expense, net |
2,008 |
12.2 |
206 |
1.3 |
|||||
Restructuring expense |
- |
- |
589 |
3.5 |
|||||
Earnings before provision for taxes on income |
2,035 |
12.4 |
3,422 |
20.6 |
(40.5) | ||||
Provision for taxes on income |
627 |
3.9 |
646 |
3.9 |
(2.9) | ||||
Net earnings |
|
8.5 |
|
16.7 |
(49.3) | ||||
Net earnings per share (Diluted) |
|
|
(50.0) | ||||||
Average shares outstanding (Diluted) |
2,798.2 |
2,781.3 |
|||||||
Effective tax rate |
30.8 |
% |
18.9 |
% |
|||||
Adjusted earnings before provision for taxes and net earnings (1) |
|||||||||
Earnings before provision for taxes on income |
|
28.2 |
|
26.6 |
5.3 | ||||
Net earnings |
|
22.1 |
|
21.4 |
2.7 | ||||
Net earnings per share (Diluted) |
|
|
1.6 | ||||||
Effective tax rate |
21.6 |
% |
19.6 |
% |
|||||
(1) See Reconciliation of Non-GAAP Financial Measures. |
|
|||||||||
Condensed Consolidated Statement of Earnings |
|||||||||
(Unaudited; in Millions Except Per Share Figures) |
SIX MONTHS | ||||||||
2012 |
2011 |
Percent | |||||||
Percent |
Percent |
Increase | |||||||
Amount |
to Sales |
Amount |
to Sales |
(Decrease) | |||||
Sales to customers |
|
100.0 |
|
100.0 |
(0.5) | ||||
Cost of products sold |
10,058 |
30.8 |
9,950 |
30.4 |
1.1 | ||||
Selling, marketing and administrative expenses |
9,980 |
30.6 |
10,271 |
31.3 |
(2.8) | ||||
Research and development expense |
3,411 |
10.5 |
3,620 |
11.0 |
(5.8) | ||||
In-process research and development |
429 |
1.3 |
- |
- |
|||||
Interest (income) expense, net |
259 |
0.8 |
215 |
0.7 |
|||||
Other (income) expense, net |
1,397 |
4.3 |
193 |
0.6 |
|||||
Restructuring expense |
- |
- |
589 |
1.8 |
|||||
Earnings before provision for taxes on income |
7,080 |
21.7 |
7,932 |
24.2 |
(10.7) | ||||
Provision for taxes on income |
1,762 |
5.4 |
1,680 |
5.1 |
4.9 | ||||
Net earnings |
$ 5,318 |
16.3 |
$ 6,252 |
19.1 |
(14.9) | ||||
Net earnings per share (Diluted) |
$ 1.91 |
$ 2.25 |
(15.1) | ||||||
Average shares outstanding (Diluted) |
2,792.4 |
2,778.1 |
|||||||
Effective tax rate |
24.9 |
% |
21.2 |
% |
|||||
Adjusted earnings before provision for taxes and net earnings (1) |
|||||||||
Earnings before provision for taxes on income |
$ 9,574 |
29.4 |
$ 9,269 |
28.3 |
3.3 | ||||
Net earnings |
$ 7,448 |
22.8 |
$ 7,295 |
22.3 |
2.1 | ||||
Net earnings per share (Diluted) |
$ 2.67 |
$ 2.63 |
1.5 | ||||||
Effective tax rate |
22.2 |
% |
21.3 |
% |
|||||
(1) See Reconciliation of Non-GAAP Financial Measures. |
|
|||||||||||||
Reconciliation of Non-GAAP Financial Measures |
|||||||||||||
Second Quarter |
Six Months YTD |
||||||||||||
(Dollars in Millions Except Per Share Data) |
2012 |
2011 |
%Incr. /(Decr.) |
2012 |
2011 |
%Incr. /(Decr.) |
|||||||
Earnings before provision for taxes on income - as reported |
|
3,422 |
(40.5) |
% |
|
|
(10.7) |
% | |||||
Intangible asset write-downs |
939 |
- |
939 |
- |
|||||||||
Net litigation |
669 |
315 |
669 |
576 |
|||||||||
Synthes integration/transaction costs and currency related |
574 |
(102) |
457 |
(102) |
|||||||||
In-process research and development |
429 |
- |
429 |
- |
|||||||||
Restructuring - Cordis |
- |
676 |
- |
676 |
|||||||||
DePuy ASR™Hip related costs |
- |
102 |
- |
187 |
|||||||||
Earnings before provision for taxes on income - as adjusted |
|
4,413 |
5.3 |
% |
|
9,269 |
3.3 |
% | |||||
Net Earnings - as reported |
|
2,776 |
(49.3) |
% |
|
6,252 |
(14.9) |
% | |||||
Intangible asset write-downs |
717 |
- |
717 |
- |
|||||||||
Net litigation |
611 |
242 |
611 |
444 |
|||||||||
Synthes integration/transaction costs and currency related |
564 |
(102) |
458 |
(102) |
|||||||||
In-process research and development |
344 |
- |
344 |
- |
|||||||||
Restructuring - Cordis |
- |
549 |
- |
549 |
|||||||||
DePuy ASR™Hip related costs |
- |
83 |
- |
152 |
|||||||||
Net Earnings - as adjusted |
|
3,548 |
2.7 |
% |
|
7,295 |
2.1 |
% | |||||
Diluted Net Earnings per share - as reported |
$ 0.50 |
1.00 |
(50.0) |
% |
$ 1.91 |
2.25 |
(15.1) |
% | |||||
Intangible asset write-downs |
0.26 |
- |
0.26 |
- |
|||||||||
Net litigation |
0.22 |
0.09 |
0.22 |
0.16 |
|||||||||
Synthes integration/transaction costs and currency related |
0.20 |
(0.04) |
0.16 |
(0.04) |
|||||||||
In-process research and development |
0.12 |
- |
0.12 |
- |
|||||||||
Restructuring - Cordis |
- |
0.20 |
- |
0.20 |
|||||||||
DePuy ASR™Hip related costs |
- |
0.03 |
- |
0.06 |
|||||||||
Diluted Net Earnings per share - as adjusted |
$ 1.30 |
1.28 |
1.6 |
% |
$ 2.67 |
2.63 |
1.5 |
% | |||||
The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations. | |||||||||||||
REPORTED SALES vs. PRIOR PERIOD ($MM) | |||||||||||
SECOND QUARTER |
SIX MONTHS | ||||||||||
% Change |
% Change | ||||||||||
2012 |
2011 |
Reported |
Operational (1) |
Currency |
2012 |
2011 |
Reported |
Operational (1) |
Currency | ||
CONSUMER SEGMENT (2) |
|||||||||||
|
|||||||||||
US |
$ 106 |
105 |
1.0% |
1.0% |
- |
$ 205 |
210 |
-2.4% |
-2.4% |
- | |
|
472 |
493 |
-4.3% |
3.5% |
-7.8% |
913 |
949 |
-3.8% |
1.7% |
-5.5% | |
WW |
578 |
598 |
-3.3% |
3.2% |
-6.5% |
1,118 |
1,159 |
-3.5% |
1.0% |
-4.5% | |
ORAL CARE |
|||||||||||
US |
159 |
158 |
0.6% |
0.6% |
- |
314 |
321 |
-2.2% |
-2.2% |
- | |
|
249 |
241 |
3.3% |
11.9% |
-8.6% |
481 |
469 |
2.6% |
8.5% |
-5.9% | |
WW |
408 |
399 |
2.3% |
7.5% |
-5.2% |
795 |
790 |
0.6% |
4.1% |
-3.5% | |
OTC/NUTRITIONALS |
|||||||||||
US |
336 |
330 |
1.8% |
1.8% |
- |
717 |
727 |
-1.4% |
-1.4% |
- | |
|
696 |
753 |
-7.6% |
0.1% |
-7.7% |
1,419 |
1,485 |
-4.4% |
0.9% |
-5.3% | |
WW |
1,032 |
1,083 |
-4.7% |
0.6% |
-5.3% |
2,136 |
2,212 |
-3.4% |
0.2% |
-3.6% | |
|
|||||||||||
US |
471 |
449 |
4.9% |
4.9% |
- |
924 |
875 |
5.6% |
5.6% |
- | |
|
442 |
480 |
-7.9% |
-0.3% |
-7.6% |
896 |
953 |
-6.0% |
-1.0% |
-5.0% | |
WW |
913 |
929 |
-1.7% |
2.2% |
-3.9% |
1,820 |
1,828 |
-0.4% |
2.2% |
-2.6% | |
WOMEN'S HEALTH |
|||||||||||
US |
80 |
121 |
-33.9% |
-33.9% |
- |
173 |
246 |
-29.7% |
-29.7% |
- | |
|
322 |
356 |
-9.6% |
-0.2% |
-9.4% |
638 |
690 |
-7.5% |
-0.8% |
-6.7% | |
WW |
402 |
477 |
-15.7% |
-8.7% |
-7.0% |
811 |
936 |
-13.4% |
-8.5% |
-4.9% | |
WOUND CARE/OTHER |
|||||||||||
US |
161 |
176 |
-8.5% |
-8.5% |
- |
296 |
305 |
-3.0% |
-3.0% |
- | |
|
125 |
131 |
-4.6% |
2.8% |
-7.4% |
238 |
245 |
-2.9% |
2.3% |
-5.2% | |
WW |
286 |
307 |
-6.8% |
-3.7% |
-3.1% |
534 |
550 |
-2.9% |
-0.6% |
-2.3% | |
TOTAL CONSUMER |
|||||||||||
US |
1,313 |
1,339 |
-1.9% |
-1.9% |
- |
2,629 |
2,684 |
-2.0% |
-2.0% |
- | |
|
2,306 |
2,454 |
-6.0% |
2.0% |
-8.0% |
4,585 |
4,791 |
-4.3% |
1.2% |
-5.5% | |
WW |
|
3,793 |
-4.6% |
0.6% |
-5.2% |
|
7,475 |
-3.5% |
0.0% |
-3.5% | |
See footnotes at end of schedule |
|||||||||||
SECOND QUARTER |
SIX MONTHS | |||||||||||
% Change |
% Change | |||||||||||
2012 |
2011 |
Reported |
Operational (1) |
Currency |
2012 |
2011 |
Reported |
Operational (1) |
Currency | |||
PHARMACEUTICAL SEGMENT (2) (4) |
||||||||||||
IMMUNOLOGY |
||||||||||||
US |
|
1,524 |
-3.5% |
-3.5% |
- |
|
2,960 |
-1.2% |
-1.2% |
- | ||
|
448 |
131 |
* |
* |
-8.1% |
890 |
275 |
* |
* |
-5.2% | ||
WW |
1,919 |
1,655 |
16.0% |
18.2% |
-2.2% |
3,814 |
3,235 |
17.9% |
19.1% |
-1.2% | ||
REMICADE |
||||||||||||
US |
890 |
836 |
6.5% |
6.5% |
- |
1,772 |
1,624 |
9.1% |
9.1% |
- | ||
US Exports (3) |
366 |
527 |
-30.6% |
-30.6% |
- |
744 |
1,017 |
-26.8% |
-26.8% |
- | ||
|
267 |
8 |
* |
* |
-8.3% |
528 |
15 |
* |
* |
-5.3% | ||
WW |
1,523 |
1,371 |
11.1% |
12.7% |
-1.6% |
3,044 |
2,656 |
14.6% |
15.6% |
-1.0% | ||
SIMPONI |
||||||||||||
US |
63 |
61 |
3.3% |
3.3% |
- |
127 |
114 |
11.4% |
11.4% |
- | ||
|
62 |
6 |
* |
* |
-5.8% |
114 |
48 |
* |
* |
-8.6% | ||
WW |
125 |
67 |
86.6% |
89.5% |
-2.9% |
241 |
162 |
48.8% |
51.3% |
-2.5% | ||
STELARA |
||||||||||||
US |
152 |
100 |
52.0% |
52.0% |
- |
281 |
205 |
37.1% |
37.1% |
- | ||
|
96 |
76 |
26.3% |
35.1% |
-8.8% |
188 |
137 |
37.2% |
45.5% |
-8.3% | ||
WW |
248 |
176 |
40.9% |
45.7% |
-4.8% |
469 |
342 |
37.1% |
40.4% |
-3.3% | ||
OTHER IMMUNOLOGY |
||||||||||||
US |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- | ||
|
23 |
41 |
-43.9% |
-39.2% |
-4.7% |
60 |
75 |
-20.0% |
-16.6% |
-3.4% | ||
WW |
23 |
41 |
-43.9% |
-39.2% |
-4.7% |
60 |
75 |
-20.0% |
-16.6% |
-3.4% | ||
INFECTIOUS DISEASES |
||||||||||||
US |
237 |
351 |
-32.5% |
-32.5% |
- |
479 |
975 |
-50.9% |
-50.9% |
- | ||
|
551 |
477 |
15.5% |
26.0% |
-10.5% |
1,064 |
784 |
35.7% |
44.3% |
-8.6% | ||
WW |
788 |
828 |
-4.8% |
1.3% |
-6.1% |
1,543 |
1,759 |
-12.3% |
-8.5% |
-3.8% | ||
INTELENCE |
||||||||||||
US |
42 |
38 |
10.5% |
10.5% |
- |
85 |
76 |
11.8% |
11.8% |
- | ||
|
49 |
41 |
19.5% |
30.4% |
-10.9% |
86 |
72 |
19.4% |
27.4% |
-8.0% | ||
WW |
91 |
79 |
15.2% |
20.8% |
-5.6% |
171 |
148 |
15.5% |
19.4% |
-3.9% | ||
LEVAQUIN/FLOXIN |
||||||||||||
US |
7 |
149 |
-95.3% |
-95.3% |
- |
25 |
571 |
-95.6% |
-95.6% |
- | ||
|
9 |
10 |
-10.0% |
-2.7% |
-7.3% |
20 |
22 |
-9.1% |
-3.9% |
-5.2% | ||
WW |
16 |
159 |
-89.9% |
-89.4% |
-0.5% |
45 |
593 |
-92.4% |
-92.2% |
-0.2% | ||
PREZISTA |
||||||||||||
US |
166 |
128 |
29.7% |
29.7% |
- |
326 |
254 |
28.3% |
28.3% |
- | ||
|
207 |
185 |
11.9% |
22.6% |
-10.7% |
371 |
325 |
14.2% |
22.2% |
-8.0% | ||
WW |
373 |
313 |
19.2% |
25.5% |
-6.3% |
697 |
579 |
20.4% |
24.9% |
-4.5% | ||
OTHER INFECTIOUS DISEASES |
||||||||||||
US |
22 |
36 |
-38.9% |
-38.9% |
- |
43 |
74 |
-41.9% |
-41.9% |
- | ||
|
286 |
241 |
18.7% |
29.1% |
-10.4% |
587 |
365 |
60.8% |
70.3% |
-9.5% | ||
WW |
308 |
277 |
11.2% |
20.2% |
-9.0% |
630 |
439 |
43.5% |
51.4% |
-7.9% | ||
REPORTED SALES vs. PRIOR PERIOD ($MM) | |||||||||||
SECOND QUARTER |
SIX MONTHS | ||||||||||
% Change |
% Change | ||||||||||
2012 |
2011 |
Reported |
Operational (1) |
Currency |
2012 |
2011 |
Reported |
Operational (1) |
Currency | ||
NEUROSCIENCE |
|||||||||||
US |
658 |
684 |
-3.8% |
-3.8% |
- |
1,332 |
1,372 |
-2.9% |
-2.9% |
- | |
|
1,056 |
1,096 |
-3.6% |
3.2% |
-6.8% |
2,029 |
2,153 |
-5.8% |
-1.3% |
-4.5% | |
WW |
1,714 |
1,780 |
-3.7% |
0.5% |
-4.2% |
3,361 |
3,525 |
-4.7% |
-1.9% |
-2.8% | |
CONCERTA/METHYLPHENIDATE |
|||||||||||
US |
146 |
234 |
-37.6% |
-37.6% |
- |
343 |
488 |
-29.7% |
-29.7% |
- | |
|
122 |
115 |
6.1% |
14.0% |
-7.9% |
233 |
223 |
4.5% |
10.1% |
-5.6% | |
WW |
268 |
349 |
-23.2% |
-20.6% |
-2.6% |
576 |
711 |
-19.0% |
-17.2% |
-1.8% | |
INVEGA |
|||||||||||
US |
76 |
76 |
0.0% |
0.0% |
- |
145 |
145 |
0.0% |
0.0% |
- | |
|
66 |
52 |
26.9% |
33.6% |
-6.7% |
118 |
103 |
14.6% |
18.8% |
-4.2% | |
WW |
142 |
128 |
10.9% |
13.6% |
-2.7% |
263 |
248 |
6.0% |
7.8% |
-1.8% | |
INVEGA SUSTENNA/ XEPLION |
|||||||||||
US |
120 |
70 |
71.4% |
71.4% |
- |
220 |
135 |
63.0% |
63.0% |
- | |
|
75 |
7 |
* |
* |
-8.8% |
136 |
7 |
* |
* |
-6.2% | |
WW |
195 |
77 |
* |
* |
-3.4% |
356 |
142 |
* |
* |
-2.4% | |
RISPERDAL CONSTA |
|||||||||||
US |
110 |
110 |
0.0% |
0.0% |
- |
223 |
224 |
-0.4% |
-0.4% |
- | |
|
245 |
294 |
-16.7% |
-9.3% |
-7.4% |
493 |
584 |
-15.6% |
-10.5% |
-5.1% | |
WW |
355 |
404 |
-12.1% |
-6.7% |
-5.4% |
716 |
808 |
-11.4% |
-7.7% |
-3.7% | |
OTHER NEUROSCIENCE |
|||||||||||
US |
206 |
194 |
6.2% |
6.2% |
- |
401 |
380 |
5.5% |
5.5% |
- | |
|
548 |
628 |
-12.7% |
-7.3% |
-5.4% |
1,049 |
1,236 |
-15.1% |
-11.7% |
-3.4% | |
WW |
754 |
822 |
-8.3% |
-4.2% |
-4.1% |
1,450 |
1,616 |
-10.3% |
-7.7% |
-2.6% | |
ONCOLOGY |
|||||||||||
US |
119 |
93 |
28.0% |
28.0% |
- |
226 |
157 |
43.9% |
43.9% |
- | |
|
467 |
459 |
1.7% |
11.2% |
-9.5% |
956 |
834 |
14.6% |
21.8% |
-7.2% | |
WW |
586 |
552 |
6.2% |
14.1% |
-7.9% |
1,182 |
991 |
19.3% |
25.3% |
-6.0% | |
DOXIL/CAELYX |
|||||||||||
US |
6 |
56 |
-89.3% |
-89.3% |
- |
13 |
120 |
-89.2% |
-89.2% |
- | |
|
7 |
82 |
-91.5% |
-89.9% |
-1.6% |
24 |
157 |
-84.7% |
-83.4% |
-1.3% | |
WW |
13 |
138 |
-90.6% |
-89.7% |
-0.9% |
37 |
277 |
-86.6% |
-85.9% |
-0.7% | |
VELCADE |
|||||||||||
US |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- | |
|
318 |
347 |
-8.4% |
-0.1% |
-8.3% |
671 |
627 |
7.0% |
13.4% |
-6.4% | |
WW |
318 |
347 |
-8.4% |
-0.1% |
-8.3% |
671 |
627 |
7.0% |
13.4% |
-6.4% | |
ZYTIGA |
|||||||||||
US |
113 |
37 |
* |
* |
- |
213 |
37 |
* |
* |
- | |
|
119 |
12 |
* |
* |
-10.0% |
219 |
17 |
* |
* |
-7.1% | |
WW |
232 |
49 |
* |
* |
-5.1% |
432 |
54 |
* |
* |
-3.6% | |
OTHER ONCOLOGY |
|||||||||||
US |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- | |
|
23 |
18 |
27.8% |
36.4% |
-8.6% |
42 |
33 |
27.3% |
33.2% |
-5.9% | |
WW |
23 |
18 |
27.8% |
36.4% |
-8.6% |
42 |
33 |
27.3% |
33.2% |
-5.9% | |
REPORTED SALES vs. PRIOR PERIOD ($MM) |
||||||||||||
SECOND QUARTER |
SIX MONTHS |
|||||||||||
% Change |
% Change |
|||||||||||
2012 |
2011 |
Reported |
Operational (1) |
Currency |
2012 |
2011 |
Reported |
Operational (1) |
Currency |
|||
TOTAL OTHER |
||||||||||||
US |
609 |
587 |
3.7% |
3.7% |
- |
1,159 |
1,166 |
-0.6% |
-0.6% |
- |
||
|
675 |
831 |
-18.8% |
-11.8% |
-7.0% |
1,365 |
1,616 |
-15.5% |
-10.9% |
-4.6% |
||
WW |
1,284 |
1,418 |
-9.4% |
-5.3% |
-4.1% |
2,524 |
2,782 |
-9.3% |
-6.6% |
-2.7% |
||
ACIPHEX/PARIET |
||||||||||||
US |
104 |
101 |
3.0% |
3.0% |
- |
200 |
210 |
-4.8% |
-4.8% |
- |
||
|
128 |
146 |
-12.3% |
-2.8% |
-9.5% |
254 |
276 |
-8.0% |
-1.5% |
-6.5% |
||
WW |
232 |
247 |
-6.1% |
-0.5% |
-5.6% |
454 |
486 |
-6.6% |
-2.9% |
-3.7% |
||
PROCRIT/EPREX |